445 related articles for article (PubMed ID: 19539320)
1. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes.
Chuang YC; Tyagi P; Huang CC; Yoshimura N; Wu M; Kaufman J; Chancellor MB
J Urol; 2009 Aug; 182(2):786-92. PubMed ID: 19539320
[TBL] [Abstract][Full Text] [Related]
2. Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves.
Chuang YC; Huang TL; Tyagi P; Huang CC
J Urol; 2016 Aug; 196(2):599-608. PubMed ID: 26724396
[TBL] [Abstract][Full Text] [Related]
3. Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats.
Chuang YC; Yoshimura N; Huang CC; Wu M; Chiang PH; Chancellor MB
Eur Urol; 2009 Jul; 56(1):159-66. PubMed ID: 18514386
[TBL] [Abstract][Full Text] [Related]
4. Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes.
Tyagi P; Chancellor MB; Li Z; De Groat WC; Yoshimura N; Fraser MO; Huang L
J Urol; 2004 Jan; 171(1):483-9. PubMed ID: 14665960
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation.
Vemulakonda VM; Somogyi GT; Kiss S; Salas NA; Boone TB; Smith CP
J Urol; 2005 Feb; 173(2):621-4. PubMed ID: 15643276
[TBL] [Abstract][Full Text] [Related]
6. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats.
Chuang YC; Yoshimura N; Huang CC; Chiang PH; Chancellor MB
J Urol; 2004 Oct; 172(4 Pt 1):1529-32. PubMed ID: 15371885
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder.
Rapp DE; Turk KW; Bales GT; Cook SP
J Urol; 2006 Mar; 175(3 Pt 1):1138-42. PubMed ID: 16469640
[TBL] [Abstract][Full Text] [Related]
8. Central inhibitory effect of intravesically applied botulinum toxin A in chronic spinal cord injury.
Munoz A; Somogyi GT; Boone TB; Smith CP
Neurourol Urodyn; 2011 Sep; 30(7):1376-81. PubMed ID: 21509809
[TBL] [Abstract][Full Text] [Related]
9. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity.
Giannantoni A; Di Stasi SM; Nardicchi V; Zucchi A; Macchioni L; Bini V; Goracci G; Porena M
J Urol; 2006 Jun; 175(6):2341-4. PubMed ID: 16697870
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation.
Lucioni A; Bales GT; Lotan TL; McGehee DS; Cook SP; Rapp DE
BJU Int; 2008 Feb; 101(3):366-70. PubMed ID: 18184328
[TBL] [Abstract][Full Text] [Related]
11. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy.
Durham PL; Cady R; Cady R
Headache; 2004 Jan; 44(1):35-42; discussion 42-3. PubMed ID: 14979881
[TBL] [Abstract][Full Text] [Related]
12. Early experimental results of using a novel delivery carrier, hyaluronan-phosphatidylethanolamine (HA-PE), which may allow simple bladder instillation of botulinum toxin A as effectively as direct detrusor muscle injection.
El Shatoury MG; DeYoung L; Turley E; Yazdani A; Dave S
J Pediatr Urol; 2018 Apr; 14(2):172.e1-172.e6. PubMed ID: 29482891
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for bladder pain with gene gun particle encoding pro-opiomelanocortin cDNA.
Chuang YC; Chou AK; Wu PC; Chiang PH; Yu TJ; Yang LC; Yoshimura N; Chancellor MB
J Urol; 2003 Nov; 170(5):2044-8. PubMed ID: 14532850
[TBL] [Abstract][Full Text] [Related]
14. Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model.
Atiemo H; Wynes J; Chuo J; Nipkow L; Sklar GN; Chai TC
Urology; 2005 Mar; 65(3):622-6. PubMed ID: 15780404
[TBL] [Abstract][Full Text] [Related]
15. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract.
Smith CP; Franks ME; McNeil BK; Ghosh R; de Groat WC; Chancellor MB; Somogyi GT
J Urol; 2003 May; 169(5):1896-900. PubMed ID: 12686869
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury.
Khera M; Somogyi GT; Kiss S; Boone TB; Smith CP
Neurochem Int; 2004 Dec; 45(7):987-93. PubMed ID: 15337297
[TBL] [Abstract][Full Text] [Related]
17. Instillation of liposomes vs dimethyl sulphoxide or pentosan polysulphate for reducing bladder hyperactivity.
Tyagi P; Hsieh VC; Yoshimura N; Kaufman J; Chancellor MB
BJU Int; 2009 Dec; 104(11):1689-92. PubMed ID: 19594739
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
Karsenty G; Elzayat E; Delapparent T; St-Denis B; Lemieux MC; Corcos J
J Urol; 2007 Mar; 177(3):1011-4. PubMed ID: 17296399
[TBL] [Abstract][Full Text] [Related]
19. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A.
Smith CP; Vemulakonda VM; Kiss S; Boone TB; Somogyi GT
Neurochem Int; 2005 Sep; 47(4):291-7. PubMed ID: 15970360
[TBL] [Abstract][Full Text] [Related]
20. Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome.
Liu HT; Chen SH; Chancellor MB; Kuo HC
PLoS One; 2015; 10(8):e0134803. PubMed ID: 26241848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
